Project website: http://www.flucop.eu/
FLUCOP is a public private consortium of twenty-two partners involving experts from six vaccine manufacturers from Europe, small and medium sized European enterprises, major academic institutions, European public health governmental institutions, and European non-governmental organisations. The project will include consultation with partners from regulatory agencies – a mechanism ensuring that the regulatory aspects of the standardisation efforts are addressed and duly considered.
FROM EXISTING EFFICACY CRITERIA TO BETTER ASSESSMENT TOOLS FOR SEASONAL FLU VACCINES
The human influenza virus is the causative agent of one of the most important infectious diseases in the world, causing frequent (seasonal) epidemics as well as pandemics, both of which cause significant morbidity and mortality worldwide. Influenza virus infects all age groups but children and adults over the topics generic form of levitra age of 65 are most at risk of types severe morbidity and mortality. Vaccination is recommended for these age groups. Vaccination remains the most effective method to control seasonal infections and the most important strategy to prepare for a possible pandemic. Despite the development and click here buy cialis online no prescription licensure of influenza vaccines along with clinical evidence of their ability to protect against influenza, the potential correlates of protection induced by these vaccines are still not fully elucidated.
The availability of a tool-box of standardised, validated assays for human influenza vaccines, agreed and used by key parties in the private and in the public sector will have tremendous impact on the Research and Development process globally, and will pave the way for future investigation and definition of correlates of protection for these vaccines.
- Professor Simon de Lusignan – Department of Health Care Management & Policy, University of Surrey
- Professor David JM Lewis – Clinical Research Centre, University of Surrey
Facts about FLUCOP
- Starting date: 1 March 2015
- End date: 28 February 2020
- Total cost: € 13.9 M
- IMI contribution: € 6.1 M
- EFPIA Coordinator: Patricia Londono-Hayes, Sanofi-Pasteur
- Managing Entity Coordinator: Donata Medaglini, Sclavo Vaccines Association and University of Siena
- Scientific Coordinator: Emanuele Montomoli, University of Siena
- Partners: 22 from 8 countries
The project kick-off meeting for FLUCOP will take place from 20-21 April 2015 at the Sanofi Pasteur, Campus Mérieux in Lyon, France.